House dust mite allergy immunotherapy - ASIT biotech

Drug Profile

House dust mite allergy immunotherapy - ASIT biotech

Alternative Names: hdm-ASIT+

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ASIT biotech
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rhinoconjunctivitis

Most Recent Events

  • 17 Oct 2017 ASIT biotech has patent protection for House dust mite allergy immunotherapy in Europe, China, Japan and India
  • 29 Mar 2017 ASIT biotech completes a phase II trial in Rhinoconjunctivitis in Germany (SC) (EudraCT2016-000557-13) before March 2017
  • 30 Nov 2016 ASIT biotech completes enrolment in its phase IIa trial for Rhinoconjunctivitis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top